Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
Standardized SEC financial data for LIXTE BIOTECHNOLOGY HOLDINGS, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001335105 · NASDAQ · Pharmaceutical Preparations.
Return on equity
-55.5%
Free cash flow
-$3.1M
Current ratio
3.88×
EPS (diluted)
$-1.26
Ratios for fiscal year 2015, standardized from SEC filings.
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
R&D expense
$1.2M
$1.7M
$1.3M
$898K
$726K
$255K
SG&A expense
$765K
$3.0M
$2.5M
$4.2M
$2.8M
$4.9M
Operating income
-$3.3M
-$6.7M
-$6.3M
-$5.1M
-$3.6M
-$5.1M
Interest expense
$4K
$7K
Standardized from LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.